Sergio Harari sul trattamento della linfangioleiomiomatosi (LAM) (in Italian)
0:00
10:40
Il Professor Sergio Harari commenta i risultati di un trial clinico di fase 2 volto a valutare l’attivita’ e la sicurezza del farmaco nintedanib come trattamento in pazienti affetti da linfangioleiomiomatosi (LAM).
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Flere episoder fra "The Lancet Respiratory Medicine in conversation with"
Gå ikke glip af nogen episoder af “The Lancet Respiratory Medicine in conversation with” - abonnér på podcasten med gratisapp GetPodcast.